Pre-IPO ReviewAggregating reviews, news, and community signal on pre-IPO companies

← Back to home

🧬 BCI/Biotech Companies

10 companies · Sorted by valuation

Colossal Biosciences

🧬 BCI/Biotech

$10.2B

Latest valuation

De-extinction and species preservation through gene editing — mammoth, thylacine, dodo

👀 0💬 0

Neuralink

🧬 BCI/Biotech

$9.65B

Latest valuation

Brain-computer interface. 1,024-electrode N1 implant. 12+ patients.

👀 0💬 1

Isomorphic Labs

🧬 BCI/Biotech

$5B

Latest valuation

Alphabet spinout building AI-first drug discovery on AlphaFold foundations

👀 0💬 0

Altos Labs

🧬 BCI/Biotech

$3B

Latest valuation

Cellular rejuvenation programming research, founded with $3B at launch

👀 0💬 0

Insitro

🧬 BCI/Biotech

$2.57B

Latest valuation

Machine-learning-driven drug discovery in metabolic, neuro and oncology disease

👀 0💬 0

Generate Biomedicines

🧬 BCI/Biotech

$2B

Latest valuation

Generative biology platform designing novel proteins and antibodies

👀 0💬 0

Xaira Therapeutics

🧬 BCI/Biotech

$2B

Latest valuation

AI-first drug discovery using protein design and generative models

👀 0💬 0

Genesis Therapeutics

🧬 BCI/Biotech

$1B

Latest valuation

AI-driven small molecule drug discovery with GEMS deep-learning platform

👀 0💬 0

Synchron

🧬 BCI/Biotech

$0.5B

Latest valuation

Endovascular BCI implanted via blood vessels — no open-brain surgery

👀 0💬 0

Precision Neuroscience

🧬 BCI/Biotech

$0.5B

Latest valuation

Reversible cortical BCI using thin-film electrode arrays placed on the brain surface

👀 0💬 0